Lv51
910 积分 2023-05-06 加入
In vivo CAR T cells move into clinical trials
5天前
已完结
OA-05 Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses
23天前
已完结
RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
25天前
已完结
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
1个月前
已完结
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
1个月前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
1个月前
已完结
MEN1 mutations mediate clinical resistance to menin inhibition
1个月前
已完结
Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China
2个月前
已完结
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
2个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
3个月前
已完结
皖公网安备34019202002308
